today's conference thank Thanks, morning, and Good Allison. everyone, call. joining on us you for
begin and financial performance with by overview XX, We months of XXXX. providing an will you during XX December ended the our operational
Tracy, will I line questions. and that, open to take your Following Jill the
significant represented company. of history one of For the the most iSpecimen, periods in XXXX the
major the we initial over $XX.X into stock accrued, debt, June, including shares accomplishments. of of and IPO, common In year, During trading million non-paid had on interest public million several $XX.X closed with we the investment-related preferred Concurrent and raising million our Nasdaq. we began $XX stock. of just converted offering, the $X million of
balance and to development the added September, of to our of improved we an business, specifically further us our our and In full August, In rate $X more million the Microcap sheet of $X.X institution accrued our and has debt allowed addition, growth Index. paid of we expansion Russell network significantly unpaid annual financing and start investing supply technology. the million additional were capital notes. bridge -IPO pre a $X.X This the with interest at a million financial X.XX% In we paid off of aggressively interest. remaining year marketplace of in the completed
the my marketplace I We will us inorganic completed allowed the later to have remarks. further placement $XX of proceeds some right of which development opportunities, which also after address growth Thanksgiving. company million biospecimen The challenge. a the and of our accelerate and private discuss platform development advance ensure platform well-positioned is Collectively, marketplace fragmented in gears, allow execute the on our the new others. to raises of capabilities strategy to as bio operational among and are that me to An XXXX compared helped a procurement by hematopoietic these and cell iSpecimen and to array the Switching organizations sequence access capital COVID-XX XXXX. to and network helping the had pursue samples, increase of supply tissues, expand our under products providing cryopreserved fluids results. of from the us These At such broader we end biospecimen XX our highlights agreement. supplier specimens organizations relationships of characterized the year, to oncology XXX and supplier network end provide to year both of fresh full unique
of number These also some XXXX. customer organizations We of us. XXX our base primarily ever included biotechnology, but from XXX centers, diagnostic and organizations customer XX% organizations We not-for-profit agencies. by unique new an at government with a and have specimens the of pharmaceutical, increase commercial grew the XXXX unique end also from of consisted as universities, companies, number defined ended of that procured research
As XXst, side customer than to more of representing iSpecimen users, registered five thousand XX% was marketplace our and total XXXX, compared of XXXX. increase December comprised side an supplier of
iSpecimen. added platform the marketplace significant more this patient also new million new two to We during XX Both and million for specimen than records of these represent records achievements milestones time.
our outlier, - to by as the we this result disease shifting categories second year. spike driven many diagnostics developers that therapeutics an full-year specimens approximately Of is one a We was of annual areas, another evidenced of XX% non compared rather demand as million, that in the a pandemic XXXX, million should was opposed overall the specimens COVID COVID and research. be non our by as growth non XXXX. in to majority business the $X.X year from of revenue half reported support. in from -pandemic we view not for the for increase of COVID-XX which came responding approximately the fiscal back It of - demand nearly just revenue to growth of do the believe business for levels, - we COVID COVID-XX as therapeutics $XX.X growth to XXXX and pre noted diagnostics For to this COVID note, the where specimens, primarily year-over-year by but markets
maybe opportunities with our to and research the our improve biospecimen sequenced laboratory in of to example include A accretive focused any that the containing continue commercial pursue a of As variance. disease reference distinct York, to category specifically with support, coronavirus category. network support will we we needing offerings seen this assess supplier on expansion and and New to customers government in recent COVID-XX good
non-COVID growing, again is to once business the our continues pandemic business pose challenges. While
to intermittent On providers side, constraints. COVID related supply healthcare face continue the
Specifically, the working during focused specimens. delivery prevalence, services of the high resources periods infection healthcare biospecimen get avoid to home, tend patients of are as collections or appointments, and healthcare research on in-person of versus delivery as sick slow personnel from
most biospecimen operating fourth collections capacity, quarter we of which the example, nearly the variant, spike Omicron supply XX% our contributed of to in less XXXX. slower than during For at was full the the chain recent of believe
infection to As a the expect to Omicron decrease, bit. rates continue we challenges supply side
to of afflicted collections that tens other custom billion neurological or system providers blood research is cerebrospinal CNS Today, biospecimens we the thousands more research. disorders. development of augmenting recent across and or blood XX% banked Turning XXXX our of to with to United and numerous in access advance liquid Asia-Pacific. supplier to biopsy numerous the of network the U.S. central biopsies, than for coming of research United provide of registered the cells existing provider for added are sample assays. offer expansion States. specimen expanded to comprehensive disorders. business biofluids federated with whole have with organization October, research. blood, biospecimen plasma we donors supplier global States particularly X increasingly our the biospecimens our we to in or to to worldwide value to support, This donation across of added suppliers in biofluids help support that access dozen suppliers we such outside global connection other of network announced suppliers people in centers selections network suppliers biospecimen This Europe, the development given related also December, expanded other important network In to help neurological includes network in from of fluid, country of December, for activity, with as nervous of Also we another accelerate of growth in provide based our network that added our the our enhances liquid us roughly biospecimen based a human In
to well-positioned prepared ahead, pursue strategies. we inorganic and organic are growth both Looking and
XXXX, earlier, placement additional an growth. throughout is a to achieve organic To this As you'll invest supply and continue capital work constraints to in we development raised private our to $XX growth, for and us expansion technology accelerated million in efforts. see plan late mentioned us supply programs alleviating position
by expand First, well our continue both gaining patients, explain data to new we more network network. network as to access samples within the suppliers to supply as supply existing our adding and will --
we XXXX, easier and accelerate to continuing in expect to and healthcare more of development broader their providers specimen platform support Second, into on-boarding it data connect. marketplace invest tools of suppliers to marketplace. In our we're our for researchers and to to the datasets make the
new it developing and suppliers internal workflow on find to finally, research. capabilities both patients, our And our tools data the of we're plan for and also search introducing to make We streamlined increase even efficiency that samples easier operations.
growth should biospecimen existing our of these All the help of accelerate business.
growth, add growth. adding overall constraints can while supply our help Turning to are business also alleviate to assessing revenue we inorganic Jason that opportunities
We are work. in of early stages the this
on financial Tracy. Now, our who Tracy I'll the to Curley, review call pass will results.
